severe or critical covid-19 disease at enrollment (day 1) (per nih treatment guideline categorization) as determined by the investigator. inability to swallow oral medication. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.

severe or critical covid-19 disease at enrollment (day 1) (per nih treatment guideline categorization) as determined by the investigator. inability to swallow oral medication. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.

1. severe or critical covid-19 disease at enrollment (day 1) (per nih treatment guideline categorization) as determined by the investigator. 2. inability to swallow oral medication. 3. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. 4. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.

1. severe or critical covid-19 disease at enrollment (day 1) (per nih treatment guideline categorization) as determined by the investigator. 2. inability to swallow oral medication. 3. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. 4. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.

1. severe or critical covid-19 disease at enrolment (day 1) (per nih treatment guideline categorization - see appendix 4) as determined by the investigator. 2. inability to swallow oral medication. 3. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. 4. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.

1. severe or critical covid-19 disease at enrolment (day 1) (per nih treatment guideline categorization - see appendix 4) as determined by the investigator. 2. inability to swallow oral medication. 3. concurrent known asthma, active tuberculosis or tuberculosis within the last 3 months, or any other condition that could compromise the well-being of the participant, or prevent, limit or confound protocol specified assessments, in the opinion of the investigator. 4. female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of participating in the study or within 6 months after last dose of study medication. males planning to conceive a child during the study or within 6 months of cessation of treatment.